Target intelligence / Profile preview

Long intergenic non-protein coding RNA 559 (LINC00559)

Target
LINC00559
Molecular classification
Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Other
01

Overview

Long intergenic non-protein coding RNA 559 (LINC00559) is a gene that encodes a long non-coding RNA of more than 200 nucleotides, transcribed from intergenic regions and not overlapping any known protein-coding genes. LINC00559 functions as a regulatory molecule involved in chromatin remodeling and the regulation of gene transcription, notably influencing cancer cell growth, colony formation, and cell cycle progression. Specifically, LINC00559 interacts with chromatin remodeling factors (such as SMARCA6) and transcription factors (such as ZBTB18) to regulate tumor suppressor gene expression, facilitating tumorigenesis, especially in lung cancer models. LINC00559 and similar lincRNAs are under investigation as both potential therapeutic targets and biomarkers in oncology, given their disease- and tissue-specific expression patterns and regulatory influence on cancer-relevant pathways. However, specific clinical drug targeting of LINC00559 is still experimental, and no approved drugs selectively modulate its function; FX1 is an example of a molecule that disrupts relevant protein-lncRNA complexes in preclinical models.

Other names
LINC00559long intergenic non-protein coding RNA 559
02

Mechanism of action

Disruption of protein–lncRNA complexes (e.g., FX1 inhibits the SMARCA6-LINC00559-ZBTB18 complex to repress cancer progression)

03

Biological functions

Regulation of gene expressionChromatin remodelingTranscriptional regulationCell cycle progressionCancer cell proliferation
04

Disease associations

CancerTumorigenesis
05

Safety considerations

Off-target effects with RNA-targeting therapiesChallenges with delivery and specificity of antisense oligonucleotides
06

Interacting drugs

FX1 (inhibitor of BTB domain)
07

Biomarkers

Tissue expression (potential biomarker for certain cancers based on lncRNA class utility, but specific validation for LINC00559 as a clinical biomarker is not documented in current sources)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 559 (LINC00559).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 559 (LINC00559).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call